Cell Reports · 2018 · 1.1K citations · 68 references
Life SciencesMedicinal ChemistryNeuroscienceDrug DiscoveryNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant TherapyNeurotransmissionSerotonergic PharmacologySerotonergic SignalingSynaptic TransmissionAntidepressant EfficacyAntidepressant ResponseIntrinsic PlasticityLead ScaffoldsMedicinal Chemistry ApplicationsPrefrontal Cortex PhysiologySerotonergic Drug DiscoverySerotonergic Mechanisms
Neuronal atrophy in the prefrontal cortex contributes to depression, and enhancing PFC plasticity is hypothesized to underlie the rapid antidepressant effects of agents such as ketamine. Psychedelics stimulate TrkB, mTOR, and 5‑HT2A signaling pathways, driving the observed structural plasticity. These compounds robustly increase neuritogenesis, spinogenesis, synapse number, and function in vitro and in vivo, underscoring their therapeutic potential and yielding lead scaffolds for fast‑acting antidepressants.
Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the dissociative anesthetic ketamine. Here, we report that, like ketamine, serotonergic psychedelics are capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo. These changes in neuronal structure are accompanied by increased synapse number and function, as measured by fluorescence microscopy and electrophysiology. The structural changes induced by psychedelics appear to result from stimulation of the TrkB, mTOR, and 5-HT2A signaling pathways and could possibly explain the clinical effectiveness of these compounds. Our results underscore the therapeutic potential of psychedelics and, importantly, identify several lead scaffolds for medicinal chemistry efforts focused on developing plasticity-promoting compounds as safe, effective, and fast-acting treatments for depression and related disorders.
68
Antidepressant effects of ketamine in depressed patients
Robert Berman, Angela Cappiello, Amit Anand et al. · Biological Psychiatry · 2000 · 3.8K citations
Medicine, Pharmacology, Psychiatry +14
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Nanxin Li, Boyoung Lee, Rongjian Liu et al. · Science · 2010 · 2.9K citations · Full text
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Anita E. Autry, Megumi Adachi, E. D. Nosyreva et al. · Nature · 2011 · 1.9K citations